Clinical Trials Browser

Phase 2 × Carcinoma, Neuroendocrine × Temozolomide × Clear all

NCT02595424 2025-12-29

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Phase 2 Active not recruiting

Somatostatinoma, Carcinoma, Neuroendocrine

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Phase 2 Active not recruiting

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03387592 2025-03-10

SENECA

Phase 2 Terminated

Carcinoma, Neuroendocrine

NCT03079440 2022-12-06

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Phase 2 Completed

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02248012 2019-12-19

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Phase 2 Completed

Carcinoma, Neuroendocrine